Psilocybin for Social Anxiety and GAD: The Clinical Evidence Base
About This Video
While psilocybin's strongest evidence base is in treatment-resistant depression and terminal illness anxiety, social anxiety disorder (SAD) and generalized anxiety disorder (GAD) are emerging research priorities — and the populations most likely to seek psilocybin informally. This NYU presentation reviews the available clinical evidence, the specific challenges of studying anxiety versus depression, and what the mechanism hypothesis predicts for these indications.
Social anxiety disorder has a specific neurobiological profile: hyperactivation of the amygdala in response to social threat cues, combined with reduced activity in the anterior cingulate cortex. Psilocybin's disruption of both amygdala response and the default mode network's self-referential processing may specifically address the self-as-socially-defective priors that maintain social anxiety.
The trial evidence reviewed: a 2023 UCLA open-label pilot (n=12) in social anxiety disorder — the first clinical trial specifically targeting SAD with psilocybin — showed statistically significant reductions in Liebowitz Social Anxiety Scale scores at 4 and 12 weeks. Effect sizes were large (Cohen's d > 1.0) but the open-label design means expectancy effects cannot be separated from pharmacological effects. A Johns Hopkins Phase 2 GAD trial began enrollment in 2025, with preliminary case series data warranting the investigation.
Key Takeaways
- UCLA SAD pilot (n=12, 2023): significant Liebowitz Social Anxiety Scale reductions at 4 and 12 weeks — the first clinical psilocybin trial specifically targeting social anxiety disorder.
- GAD: Johns Hopkins Phase 2 trial enrolling 2025; the REBUS model predicts psilocybin should reduce hyperactive threat prediction.
- The anxiety paradox in psilocybin therapy: increased session anxiety can be therapeutic by exposing the patient to feared internal states with reduced defensive capacity.
- Amygdala hyperactivation and self-as-socially-defective priors are the specific targets for social anxiety — both theoretically addressable by psilocybin's mechanism.
- Evidence quality caveat: SAD and GAD evidence is substantially weaker than depression and terminal anxiety — Phase 2 trials in progress should be monitored for results in 2026-2027.
Dive Deeper
Continue exploring this topic on LearnShrooms: